General Information
Version
8.0
Revision date
2023-08-29
Product name
5-METHYL-5-NITRO-2-HEXANONE
CAS No.
4604-49-3
REACH No
A
Emergency telephone
+(45)-6991 8573, +(45)-8212 1212
Icons in SDS
Company Information
company name
Merck Life Science ApS
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H310
Hazard statements
Code
Statements
H310
Fatal in contact with skin
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H310 Fatal in contact with skin.
Precautionary statements
P262 Do not get in eyes, on skin, or on clothing. P264 Wash skin thoroughly after handling. P280 Wear protective gloves/ protective clothing. P302 + P352 + P310 IF ON SKIN: Wash with plenty of water. Immediately call a POISON CENTER/ doctor. P361 + P364 Take off immediately all contaminated clothing and wash it before reuse. P405 Store locked up.
Supplemental label elements
none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Acute toxicity, Dermal (Category 1), H310 For the full text of the H-Statements mentioned in this Section, see Section 16.
